[
  {
    "ts": null,
    "headline": "Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. The medication is being studied as a potential treatment for hyperlipidemia, a condition […]",
    "url": "https://finnhub.io/api/news?id=a2c2316ad2216d6c28ce72b3ab8dfafecec7508c0054140f01c5b5cee6c415f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749675063,
      "headline": "Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials",
      "id": 135199941,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. The medication is being studied as a potential treatment for hyperlipidemia, a condition […]",
      "url": "https://finnhub.io/api/news?id=a2c2316ad2216d6c28ce72b3ab8dfafecec7508c0054140f01c5b5cee6c415f3"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=78ce5d8376ac8feb308af4351274d88ebf8457d58418455708cc5578c1b4490e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749659640,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 135215712,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=78ce5d8376ac8feb308af4351274d88ebf8457d58418455708cc5578c1b4490e"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot received authorization from the U.S. Food and Drug Administration (FDA). This shot shields infants up to the age of one from the respiratory syncytial virus during their first RSV period. RSV refers […]",
    "url": "https://finnhub.io/api/news?id=eac8441a70bd17edc69000629c0bd2f6ea2c8aaddd2e94c9b89ca04d69a34435",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749655804,
      "headline": "Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA",
      "id": 135192167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot received authorization from the U.S. Food and Drug Administration (FDA). This shot shields infants up to the age of one from the respiratory syncytial virus during their first RSV period. RSV refers […]",
      "url": "https://finnhub.io/api/news?id=eac8441a70bd17edc69000629c0bd2f6ea2c8aaddd2e94c9b89ca04d69a34435"
    }
  },
  {
    "ts": null,
    "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
    "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
    "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651653,
      "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
      "id": 135184593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
      "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?",
    "summary": "JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.",
    "url": "https://finnhub.io/api/news?id=34ea8b51637d8d134aa06a97ce8ac2938b88b3e8b30501f3c8339a2201efd26e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749648960,
      "headline": "JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?",
      "id": 135192169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.",
      "url": "https://finnhub.io/api/news?id=34ea8b51637d8d134aa06a97ce8ac2938b88b3e8b30501f3c8339a2201efd26e"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Value Fund Q1 2025 Commentary",
    "summary": "Artisan Value Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=c9e7e2d779c9d4472f759f28f33d7273267d05a68cc082bea1716eee12e41bea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749630000,
      "headline": "Artisan Value Fund Q1 2025 Commentary",
      "id": 135179100,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c9e7e2d779c9d4472f759f28f33d7273267d05a68cc082bea1716eee12e41bea"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The Dow Performance Ahead Of The Mag 7 Return",
    "summary": "The Dogs of the Dow investment strategy has generated mixed results over the years but 2025 is proving to be a favorable one for this group of stocks.",
    "url": "https://finnhub.io/api/news?id=1bcb8cebe0a8eb2e29632d680ad3448176979f000f1eea3b5022e15e5a6b68f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749613500,
      "headline": "Dogs Of The Dow Performance Ahead Of The Mag 7 Return",
      "id": 135177326,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The Dogs of the Dow investment strategy has generated mixed results over the years but 2025 is proving to be a favorable one for this group of stocks.",
      "url": "https://finnhub.io/api/news?id=1bcb8cebe0a8eb2e29632d680ad3448176979f000f1eea3b5022e15e5a6b68f8"
    }
  }
]